On Tuesday, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was -1.30% drop from the session before settling in for the closing price of $8.49. A 52-week range for AUPH has been $4.71 – $10.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 3168.98%. When this article was written, the company’s average yearly earnings per share was at 105.86%. With a float of $128.85 million, this company’s outstanding shares have now reached $143.83 million.
Considering the fact that the conglomerate employs 300 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 86.5%, operating margin of -9.74%, and the pretax margin is -9.68%.
Aurinia Pharmaceuticals Inc (AUPH) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aurinia Pharmaceuticals Inc stocks. The insider ownership of Aurinia Pharmaceuticals Inc is 10.01%, while institutional ownership is 40.72%. The most recent insider transaction that took place on Nov 11 ’24, was worth 38,416. In this transaction Director of this company sold 4,557 shares at a rate of $8.43, taking the stock ownership to the 13,356 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Director sold 5,241 for $8.43, making the entire transaction worth $44,182. This insider now owns 12,672 shares in total.
Aurinia Pharmaceuticals Inc (AUPH) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.19 earnings per share (EPS) during the time that was less than consensus figure (set at -0.16) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 105.86% per share during the next fiscal year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
You can see what Aurinia Pharmaceuticals Inc (AUPH) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.44. Likewise, its price to free cash flow for the trailing twelve months is 41.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.16, a number that is poised to hit 0.01 in the next quarter and is forecasted to reach 0.59 in one year’s time.
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
Compared to the last year’s volume of 1.61 million, its volume of 2.33 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 79.92%. Additionally, its Average True Range was 0.32.
During the past 100 days, Aurinia Pharmaceuticals Inc’s (AUPH) raw stochastic average was set at 89.84%, which indicates a significant increase from 80.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.68% in the past 14 days, which was higher than the 44.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.19, while its 200-day Moving Average is $6.06. Nevertheless, the first resistance level for the watch stands at $8.55 in the near term. At $8.72, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.85. If the price goes on to break the first support level at $8.24, it is likely to go to the next support level at $8.11. Should the price break the second support level, the third support level stands at $7.94.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Key Stats
There are 143,179K outstanding shares of the company, which has a market capitalization of 1.20 billion. As of now, sales total 175,510 K while income totals -78,020 K. Its latest quarter income was 67,770 K while its last quarter net income were 14,350 K.
